Skip to content
OpenCapital
Get started

LB Pharmaceuticals Inc Common Stock LBRX Q3 2025 earnings

Reported November 6, 2025 · Before market open

Diluted EPS-$0.61Miss by $0.04
EPS estimate-$0.57

Next report

Aug 11, 2026 (In 4 weeks)
EPS estimate-$0.84

Financials

Q3 2025

Income statement

See full
Net income-$3.6M+74.9%
EPS (diluted)-$0.61+98.5%

Balance sheet

See full
Cash & equivalents$269.7M—
Total debt$3.7M—
Total equity$310.2M+439%
Total assets$320.7M—

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$354.37M—
Enterprise value$88.3M—

Returns & leverage

See full
Debt / equity0×—
Current ratio47.6×—

Versus estimates

Diluted EPS

Q1 2026-$0.67Beat by $0.08Q4 2025-$0.45In line
Q3 2025-$0.61Miss by $0.04

Ask the moment LB Pharmaceuticals Inc Common Stock reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did LB Pharmaceuticals Inc Common Stock report Q3 2025 earnings?
LB Pharmaceuticals Inc Common Stock (LBRX) reported Q3 2025 earnings on November 6, 2025 before market open.
What were LB Pharmaceuticals Inc Common Stock's Q3 2025 revenue and EPS?
LB Pharmaceuticals Inc Common Stock reported diluted EPS of $-0.61 for Q3 2025.
Did LB Pharmaceuticals Inc Common Stock beat estimates in Q3 2025?
EPS missed the consensus estimate of $-0.57 by $0.04.
Where can I find LB Pharmaceuticals Inc Common Stock's Q3 2025 SEC filings?
You can read the 8-K earnings release (0001193125-25-268154) and the 10-Q periodic report (0001193125-25-268174) directly on SEC EDGAR. The filing index links above go to sec.gov.